Is NCT07284290 recruiting in Richmond, VA?

Yes, NCT07284290 is currently recruiting participants at its Richmond, VA location. This dementia with lewy bodies clinical trial is actively enrolling qualified participants.

How do I join the dementia with lewy bodies clinical trial in Richmond?

To join this clinical trial in Richmond, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Richmond clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Dementia With Lewy Bodies Clinical Trial in Richmond, VA

About This Dementia With Lewy Bodies Study in Richmond

The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrated research plan

Sponsor: Virginia Commonwealth University

Who Can Participate

Inclusion Criteria

Age range: 50 ≤ age \< 90.

Diagnosis of dementia with Lewy bodies (DLB), Parkinson disease dementia (PDD), Parkinson disease with Mild Cognitive Impairment (PD-MCI), Mild Cognitive Impairment with Lewy bodies (MCI-LB).

DLB participants must fulfill criteria for clinically probable DLB based on the 2017 4th consensus report of the DLB consortium.

PDD participants must meet criteria for clinically probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease and must also meet criteria for probable PDD based on the 2007 Movement Disorders Society clinical diagnostic criteria.

PD-MCI participants must meet criteria for clinically probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease and meet criteria for Mild Cognitive Impairment on cognitive testing at screening.

MCI-LB participants with must meet established research criteria.

Capacity to provide informed consent or, if unable, availability of a legally authorized representative or guardian who can provide informed consent.

Availability of informant (for participants meeting criteria for dementia).

Ability and willingness to comply with the study-related procedures.

Fluent in spoken and written English (due to cognitive testing)

Exclusion Criteria

History of cognitive disorder or psychiatric disorder other than that related to dementia with Lewy bodies or Parkinson disease dementia.

History of deep brain stimulation or any neurosurgical procedure.

History of structural brain disease or known significant cerebrovascular disease.

History of seizures or epilepsy and/or use of sodium channel blockers, i.e. carbamazepine, oxcarbazepine, phenytoin, topiramate, lamotrigine, felbamate, zonisamide, rufinamide, lacosamide, eslicarbazepine, and valproate.

Greater than two alcoholic drinks per day for men and one per day for women.

Regular use of benzodiazepines or barbiturates. (If benzodiazepines are taken as needed only, these medications cannot be taken within 5 half-lives of screening visit or between screening visit and EEG.)

Severe dementia (based on PI assessment of subject dependence level for instrumental activities of daily living)

Any contraindication to brain MRI.

Any medical condition that would interfere with ability to complete all study procedures.

Participants must not be pregnant, planning to become pregnant, or father a child for the duration of the study Inclusion Criteria: Arm 2 (Cholinesterase inhibitor cohort) inclusion criteria:

Completed Aim 1.

Clinical diagnosis of LBD (DLB or PDD) with CF.

Not taking a cholinesterase inhibitor and has not taken a cholinesterase inhibitor in the previous 90 days.

Ability and willingness to comply with the ChEI Cohort procedures (including galantamine administration), or a caregiver willing and able to ensure compliance. Exclusion Criteria: Arm 2 (Cholinesterase inhibitor cohort) exclusion criteria:

Severe hepatic impairment.

Renal failure.

Significant bradycardia (\<50 bpm) at screening or history of AV block.

Any contraindication to galantamine administration based on PI discretion. Inclusion criteria: Arm 3 (Healthy Controls)

Age range: 50 ≤ age \< 90.

Healthy controls should not have any known neurologic conditions that could interfere with study procedures or results.

Capacity to provide informed consent or, if unable, availability of a legally authorized representative or guardian who can provide informed consent.

Availability of informant (for participants meeting criteria for dementia).

Ability and willingness to comply with the study-related procedures.

Fluent in spoken and written English (due to cognitive testing). Exclusion Criteria: Arm 3 (Healthy Controls)

No History of cognitive disorder or psychiatric disorder other than that related to dementia with Lewy bodies or Parkinson disease dementia.

No History of deep brain stimulation or any neurosurgical procedure.

No History of structural brain disease or known significant cerebrovascular disease.

No History of seizures or epilepsy and/or use of sodium channel blockers, i.e. carbamazepine, oxcarbazepine, phenytoin, topiramate, lamotrigine, felbamate, zonisamide, rufinamide, lacosamide, eslicarbazepine, and valproate.

Any medical condition that would interfere with ability to complete all study procedures.

Participants must not be pregnant, planning to become pregnant, or father a child for the duration of the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Richmond?

Yes, this clinical trial (NCT07284290) has an active research site in Richmond, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Dementia With Lewy Bodies Treatment Options in Richmond, VA

If you're searching for dementia with lewy bodies treatment options in Richmond, VA, this clinical trial (NCT07284290) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Richmond research site is actively enrolling participants for this clinical trial. You'll receive care from experienced dementia with lewy bodies specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all dementia with lewy bodies clinical trials near you to find additional studies recruiting in your area.

Dementia With Lewy Bodies Clinical Trial in Richmond, VA

Expert Care in Richmond

IRB Approved

No-Cost Care

Apply for This Richmond Location

Why Participate?

Simple Process